In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper

C. Mayorga 1, 2 G. Celik 3 P. Rouzaire 4 P. Whitaker 5 P. Bonadonna 6 J. Rodrigues-Cernadas 7 A. Vultaggio 8 K. Brockow 9 J. Caubet 10 J. Makowska 11 A. Nakonechna 12 S. Romano 13 M. I. Montañez 14 J. Laguna 15 G. Zanoni 16 J. Gueant 17 H. Oude Elberink 18 J. Fernandez 19 S. Viel 20 P. Demoly 21 M. J. Torres 2
3 Division of Immunology and Allergy [Ankara, turkey]
Department of Chest Diseases [Ankara, Turkey]
8 Immunoallergology Unit [Careggi Hospital]
Department of Biomedicine [Careggi Hospital]
10 Pediatric Allergy Unit [Geneva University Hospitals]
Department of Child and Adolescent [Geneva University Hospitals]
15 Allergy Unit [Cruz Roja-Madrid]
Hospital Central de la Cruz Roja San Jose y Santa Adela
16 Section of Immunology [University of Verona]
Department of Pathology and Diagnostics [Verona]
19 Allergy Section [Alicante]
Universidad de Alicante = University of Alicante
21 Equipe EPAR - Épidémiologie des maladies Allergiques et Respiratoires
iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
Abstract : Drug hypersensitivity reactions (DHRs) are a matter of great concern, both for outpatient and in hospital care. The evaluation of these patients is complex, because invivo tests have a suboptimal sensitivity and can be time-consuming, expensive and potentially risky, especially drug provocation tests. There are several currently available invitro methods that can be classified into two main groups: those that help to characterize the active phase of the reaction and those that help to identify the culprit drug. The utility of these invitro methods depends on the mechanisms involved, meaning that they cannot be used for the evaluation of all types of DHRs. Moreover, their effectiveness has not been defined by a consensus agreement between experts in the field. Thus, the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology has organized a task force to provide data and recommendations regarding the available invitro methods for DHR diagnosis. We have found that although there are many invitro tests, few of them can be given a recommendation of grade B or above mainly because there is a lack of well-controlled studies, most information comes from small studies with few subjects and results are not always confirmed in later studies. Therefore, it is necessary to validate the currently available invitro tests in a large series of well-characterized patients with DHR and to develop new tests for diagnosis.
Type de document :
Article dans une revue
Allergy, Wiley, 2016, 71 (8), pp.1103 - 1134. 〈10.1111/all.12886〉
Liste complète des métadonnées

https://hal.univ-lorraine.fr/hal-01663032
Contributeur : Ngere Ul <>
Soumis le : mercredi 13 décembre 2017 - 16:29:48
Dernière modification le : mercredi 10 janvier 2018 - 12:08:01

Identifiants

Collections

Citation

C. Mayorga, G. Celik, P. Rouzaire, P. Whitaker, P. Bonadonna, et al.. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy, Wiley, 2016, 71 (8), pp.1103 - 1134. 〈10.1111/all.12886〉. 〈hal-01663032〉

Partager

Métriques

Consultations de la notice

10